Background {#Sec1}
==========

Consensus exists that overt hyperglycemia (\>150 mg/dl) in patients admitted to the intensive care unit (ICU) should be treated to improve morbidity and survival \[[@CR1]\]. However, there is little agreement on the ideal target range of glycemia \[[@CR2]\]. Strict glycemic control (80--110 mg/dl) is no longer recommended for most ICUs, but in highly standardized ICUs a strict target may be feasible without increasing hypoglycemia. Achieving strict glycemic control is a complex task since during ICU stay severity of illness and degree of insulin resistance may fluctuate, nutritional delivery may change, and interventions (e.g., administration of corticosteroids) may produce frequent changes in insulin needs \[[@CR2]\]. Therefore, multiple insulin infusion protocols (IIPs) were created, all meant to balance efficacy with safety (avoid hypoglycemia), and attainability (nursing workload).

So far, no single IIP has been established as the most effective for obtaining tight glycemic control. Earlier observational studies and randomized controlled trials (RCTs) in medical ICU (MICU) or mixed ICU settings, and targeting a glycemia between 80 and 110 mg/dl, reported that 22--60% of all blood glucose values were in target for paper-based IIPs \[[@CR3]--[@CR14]\], compared to 42--69% for computerized decision-supported algorithms \[[@CR4], [@CR10], [@CR11], [@CR14], [@CR15]\]. The efficacy and safety of different IIPs on glycemic control have recently been investigated using computer simulation models \[[@CR16], [@CR17]\] and in RCTs in cardiac surgery patients \[[@CR18], [@CR19]\]. However, to the best of our knowledge, comparing the effect of different IIPs on glucose control has never been investigated in MICU patients. With this pooled data analysis of two published prospective RCTs \[[@CR5], [@CR6]\], we assessed the clinical performance of two IIPs (Leuven versus modified Yale protocol) in patients admitted to MICU, by means of continuous glucose monitoring (CGM), allowing a complete picture of glucometrics.

Methods {#Sec2}
=======

This is a pooled data analysis of two prospective RCTs conducted at the medical ICUs of the Antwerp University Hospital (45 beds, including 14 MICU beds) and Middelheim Hospital, a university-affiliated tertiary care center (36 beds, including 13 MICU beds) \[[@CR5], [@CR6]\]. Patients were recruited between 04/2004 and 03/2005 for the first study and between 07/2007 and 09/2009 for the second study. Both MICUs applied the same standards of care, with a nurse-to-patient ratio between 1:2.5 and 1:3.0. Each patient or the closest family member gave written informed consent. Patients were included if they were between 18 and 75 years, treated by IV insulin, and expected to stay in MICU for ≥3 days. Patients were not enrolled if pregnant, if surgery was the reason for admission, or if a do not reanimate code was present. The studies were approved by the ethics committees of both hospitals (Middelheim approval no. 2345 and UZA 6/43/211) and conducted in accordance with the amended Declaration of Helsinki.

Severity of illness was scored using the Acute Physiology And Chronic Health Evaluation II (APACHE-II) and the Sequential Organ Failure Assessment (SOFA) score \[[@CR20], [@CR21]\]. The neurologic score was zero when patients were sedated. Enteral nutrition was started as soon as possible, at 25 kcal/kg body weight per day.

Glucose monitoring {#Sec3}
------------------

Forty-eight-hour CGM was initiated within the first 48 h after admission using a microdialysis-based device that is not equipped with alarms (GlucoDay^®^ in the first study and GlucoDay^®^S in the second study, A. Menarini Diagnostics, Florence, Italy). The methodology has been described before \[[@CR5], [@CR6]\]. Briefly, a microdialysis fiber (Medica, Medolla, Italy) was inserted subcutaneously into the periumbilical region using an 18-gauge Teflon^®^ (DuPont, Wilmington, DE) catheter as a guide. The device does not use any coagulant. The device uses a glucose oxidase-based amperometric biosensor to measure glucose concentrations in the interstitial dialysate every 3 min over a 48 h period.

Data analysis for accuracy and glucometrics was performed by applying, in silico to the CGM signal, a two-point calibration according to the manufacturer's requirements (one calibration every 24 h). This was performed in order to avoid an overestimation of the system's accuracy if one uses a higher number of calibration points. In the RT-CGM group, however, to be as safe as possible and to account for possible changes in subcutaneous glucose recovery due to hemodynamic alterations (e.g., hypotension, shock, vasoactive drugs), for each sensor, a six-point calibration was performed (after 2, 6, 12, 18, 24, and 36 h) using arterial BG values, but these data were not used for statistical analysis \[[@CR6]\]. This was done to assure that the glucose readings and trends shown by RT-CGM would be clinically reliable. At present, RT-CGM is becoming more common practice, but at the time of the study, a real-time CGM device was not approved to make clinical adjustments of insulin therapy, and our ethical committee would not approve clinical decisions to be made solely on the basis of RT-CGM at that time. In order to avoid clinical decisions being made on potentially inaccurate CGM data, nurses had to take an additional arterial blood glucose sample. Thus, direct corroboration of the data was explicitly needed. The RT-CGM system was thus used only as a prompt to take an extra blood glucose sample if the rate of change in glucose exceeded 25 mg/dl per 30 min. Since no differences in glucometrics were observed in the REGIMEN trial between in patients randomized to RT-CGM versus blinded CGM, we pooled the data. For all patients, adjustments of insulin therapy were made on the basis of arterial blood glucose values \[[@CR6]\].

Insulin infusion protocols {#Sec4}
--------------------------

Twenty-two patients received continuous IV insulin (regular insulin Actrapid; Novo Nordisk, Bagsvaerd, Denmark) according to the Leuven protocol, targeting a blood glucose between 80 and 110 mg/dl \[[@CR5], [@CR13]\]. Thirty-five subjects were treated with IV insulin (insulin aspart, Novo Nordisk, Bagsvaerd, Denmark) according to a modified Yale protocol, targeting a blood glucose level between 80 and 120 mg/dl \[[@CR6]\].

In both groups, arterial blood glucose levels were measured using an on-site blood gas analyzer (Rapidlab^®^ 1265, Siemens, München, Germany) and they were used to adjust the insulin infusion rate. Insulin in a concentration of 50 units in 50 cc 0.9% NaCl was infused using the Injectomat Agilia^®^ syringe infusion system (flow rate change: range 0.1--200 ml/h, Fresenius Kabi, Bad Homburg, Germany). In both groups, the arterial blood glucose sampling interval varied between 1 and 4 h. For more details on the insulin infusion protocols, the reader is referred to the original publications \[[@CR5], [@CR6]\].

Outcome parameters {#Sec5}
------------------

The percentage of time spent in the target range of glycemia (80--110 mg/dl) was the primary outcome parameter. Secondary outcome variables were percentages of time spent in hypoglycemia (\<60 mg/dl), in hyperglycemia (\>150 and \>200 mg/dl), and parameters of glycemic fluctuations (SD: standard deviation \[[@CR22]\], CV: coefficient of variation \[[@CR22]\], MAGE: mean amplitude of glucose excursions \[[@CR23]\], CONGA: continuous overlapping net glycemic action \[[@CR24]\], and MODD: mean of daily differences \[[@CR25]\]. We also calculated the low blood glucose index (LBGI) and the high blood glucose index (HBGI) as measures of risk of hypo- and hyperglycemia \[[@CR26]\]. All glucometric data reported are those calculated using CGM data. A CGM reading \<60 mg/dl, confirmed by an arterial blood glucose sample \<60 mg/dl, lasting for \>6 min (6 min being the time of two CGM measurements) was defined as a hypoglycemic event. We rigorously followed the recommendations on measurement of blood glucose and reporting glycemic control in critically ill adults \[[@CR27]\].

Statistical analysis {#Sec6}
--------------------

Results were analyzed using SPSS (SPSS Inc., Chicago, USA). Distributions of continuous data were tested for normality by Kolmogorov--Smirnov test. The unpaired *t* test or Mann--Whitney *U* test were used to determine differences between groups, with Bonferroni adjustments for multiple comparisons. Data are expressed as mean ± SD or median \[25th--75th percentile\]. Differences in distributions of categorical data were evaluated by *χ* ^2^ or Fisher's exact test. Stepwise forward logistic or linear regression analysis was performed to assess the strength and independency of associations. A two-tailed *p* \< 0.05 was considered significant.

Results {#Sec7}
=======

Over 63,000 CGM data points were analyzed from 57 adults (men/women: 30/27, non-diabetic/diabetic: 36/21) admitted to the MICU. Mean age was 64 ± 12 years. They were severely ill as demonstrated by a mean APACHE-II score of 28 ± 7 and SOFA score of 10 ± 4. Table [1](#Tab1){ref-type="table"} shows reasons for admission and interventions used.Table 1Baseline characteristics, interventions used and glucometrics of patients treated by the Leuven versus Yale protocolTotal cohortLeuvenYaleStatisticsNumber of patients572235*p* valuePatient demographics Men/women30/2713/917/18NS Diabetic status (no/type1/type2)36/6/159/4/927/2/60.0016 Age (years)64 ± 1260 ± 1366 ± 100.055 BMI (kg/m^2^)26.8 ± 5.427.5 ± 7.126.3 ± 4.0NSAdmission reason Septic shock22139NS Neurologic disease/coma9090.004 Cardiopulmonary resuscitation918NS Respiratory failure615NS Cardiogenic shock734NS Other440NSSeverity of illnessAPACHE-II score28 ± 727 ± 728 ± 7NSSOFA score10 ± 49 ± 411 ± 30.072Clinical interventions Mechanical ventilation441628NS Vasopressor therapy351421NS Inotropic therapy20614NS Hemodialysis1495NS No/total parenteral/enteral feeding17/17/239/10/38/7/200.003 Glucocorticoids271215NS Blood transfusion15411NS Antibiotics461927NSOutcome parameters LOS in ICU (days)15 ± 911 ± 617 ± 100.019 In hospital mortality20711NSInsulin dose Day 1 (units)138 (48--190)50 (27--80)0.001 Day 2 (units)116 (54--116)56 (28--81)0.006Glucose parameters HbA1c (%)6.3 (5.8--7.0)6.0 (5.7--6.6)NS HbA1c (mmol/mol)45 (40--53)42 (39--49)NS Median glycemia (mg/dl)128 (106--154)118 (108--128)NS % of time at glycemia  \<60 mg/dl5 (1--8)0 (0--2)0.001  80--110 mg/dl26 ± 1137 ± 150.001  \>150 mg/dl29 ± 2317 ± 13\<0.0001  \>200 mg/dl13 ± 193 ± 5\<0.0001  60--150 mg/dl66 ± 2481 ± 7\<0.0001  70--180 mg/dl69 ± 1991 ± 10\<0.0001 Nr of art blood glc measurements/day10 ± 210 ± 4NS Glucose variability parameters  SD (mg/dl)47 (31--71)28 (21--37)0.001  Coefficient of variation (%)36 (26--50)23 (19--31)0.001  IQR66 (47--82)37 (27--43)\<0.0001  MAGE (mg/dl)73 (47--128)52 (37--83)0.061 (NS)  MODD (mg/dl)60 (33--94)35 (26--41)0.001  M-10010 (4--25)4 (2--5)\<0.0001  CONGA1 (mg/dl)20 (14--39)15 (13--24)NS  CONGA2 (mg/dl)30 (22--53)23 (18--34)0.036  CONGA4 (mg/dl)38 (28--66)29 (20--43)0.012  LBGI2.6 (1.0--3.7)0.7 (0.4--1.4)0.011  HBGI2.5 (1.0--8.0)1.3 (0.5--1.8)0.018  Glucose variability42 (29--67)28 (20--34)0.001Data are presented as numbers, as mean ± SD or median (25--75th percentile)*LOS in ICU* length of stay in ICU, *IQR* interquartile range, *MAGE* mean amplitude of glycemic excursions, *MODD* mean of daily differences, *LBGI* low blood glucose index, *HBGI* high BGI

Comparison of Leuven versus Yale protocol {#Sec8}
-----------------------------------------

Twenty-two subjects were treated using the Leuven protocol and 35 by the Yale protocol. The distribution of diabetic subjects differed between groups (13/22 Leuven vs. 8/35 Yale; *p* = 0.0016). Patients in the Yale group tended to be older. Reasons for admission were comparable between groups with exception of neurologic disease/coma. Feeding habits were different in the two groups (*p* = 0.003) with enteral feeding being less frequently used in the Leuven group (3/22 vs. 20/35). The APACHE-II score was similar, whereas the SOFA score tended to be higher in the Yale group.

Patients in the Leuven group required much more IV insulin compared to those treated by the Yale protocol (Table [1](#Tab1){ref-type="table"}). Despite a similar number of arterial blood glucose measurements, patients in the Yale protocol had better glucometrics with a higher percentage of time in target glycemia (80--110 mg/dl) (37 ± 15 vs. 26 ± 11%, *p* = 0.001) and a lower percentage of time spent in hypoglycemia (0\[0--2\] vs. 5\[1--8\]%, *p* = 0.001). Also percentage of time spent between 60 and 150 mg/dl (81 ± 7 vs. 66 ± 24%, *p* \< 0.0001), 80--125 mg/dl (57 ± 18 vs. 36 ± 21%, *p* \< 0.0001), between 80 and 145 mg/dl (74 ± 17 vs. 48 ± 23, *p* \< 0.0001), and between 70 and 180 mg/dl (91 ± 10 vs. 69 ± 19%, *p* \< 0.0001) was higher in the Yale group. Figure [1](#Fig1){ref-type="fig"} shows the time-in-band for the different ranges of targets for both groups. Median glycemia, however, did not differ between groups (118\[108--128\] (log: 114\[105--125\]) vs. 128\[106--154\] (log: 122\[99--136\]) mg/dl) (Table [1](#Tab1){ref-type="table"}). Glycemic variability was less pronounced with the use of the Yale protocol (median\[IQR\] SD 28\[21--37\] vs. 47\[31--71\] mg/dl, *p* = 0.001; median CV 23\[19--31\] vs. 36\[26--50\]%, *p* = 0.001; median MODD 35\[26--41\] vs. 60\[33--94\] mg/dl, *p* = 0.001). Significant better LBGI and HBGI were observed in the Yale group (Table [1](#Tab1){ref-type="table"}). Eight insulin/glucose plots comparing non-diabetic and diabetic patients treated according to the Leuven protocol versus according to the modified Yale protocol are shown in Fig. [2](#Fig2){ref-type="fig"}, providing the reader with a good visual image.Fig. 1Average percentage time in range and SD over the groups (Yale vs. Leuven) for the different glycemia target ranges. *P* \< 0.0001 for all three ranges Fig. 2Insulin glucose plots comparing 4 non-diabetic and 4 diabetic patients treated according to the Leuven protocol versus according to the modified Yale protocol. *CGM* continuous glucose monitoring

Characteristics of subjects achieving strict versus above-target glycemic control {#Sec9}
---------------------------------------------------------------------------------

Subjects achieving strict glycemic control (*n* = 19), defined as having an average glycemia ≤110 mg/dl, did not differ with regard to gender, diabetic status, age, BMI, reason for admission, severity of illness, and interventions used as compared to the ones not obtaining an average glycemia ≤110 mg/dl, with the exception of the use of glucocorticoids (*p* = 0.001) (Table [2](#Tab2){ref-type="table"}). The distribution according to insulin infusion protocol used (Leuven vs. Yale) also did not differ between groups. Insulin doses infused and a number of arterial blood glucose measurements were similar as well. Most glucometrics (% of time within target) including glycemic variability (SD, MODD, LBGI and HBGI) were better in the group achieving strict glycemic control. Logistic regression analysis could not identify type of IIP, diabetes status, age, BMI, or APACHE-II score as independent parameters for strict glucose control. The only parameter which showed an independent association with strict glucose control was the administration of glucocorticoids (*p* = 0.001).Table 2Baseline characteristics, interventions used and glucometrics of patients reaching an average glycemia ≤110 mg/dl versus those with an average glycemia \>110 mg/dlAvg glyc ≤ 110 mg/dlAvg glyc \>110 mg/dlStatisticsNumber of patients1938Patient demographics Men/women8/1122/16NS Diabetic status (no/type1/type2)14/1/423/4/11NS Age (years)65 ± 1163 ± 12NS BMI (kg/m^2^)26.3 ± 3.827.1 ± 6.1NSSeverity of illness APACHE-II score27 ± 628 ± 7NS SOFA score10 ± 410 ± 3NSClinical interventions Mechanical ventilation1431NS Vasopressor therapy1223NS Hemodialysis59NS No/total parenteral/enteral feeding4/6/913/11/14NS Glucocorticoids15120.01 Antibiotics1729NSProtocol (Leuven/Yale)7/1215/23NSInsulin dose Day 1 (units)62 (33--133)63 (39--128)NS Day 2 (units)67 (23--101)70 (42--120)NSGlucose parameters HbA1c (%)6.1 (5.6--6.7)6.0 (5.8--6.9)NS HbA1c (mmol/mol)43 (38--50)70 (42--120)NS Median glycemia (mg/dl)104 (100--108)128 (119--141)\<0.0001 % of time at glycemia  \<60 mg/dl5 (0--8)0 (0--4)0.067  80--110 mg/dl41 ± 1427 ± 130.001  \>150 mg/dl6 ± 628 ± 18\<0.0001  \>200 mg/dl1 ± 210 ± 160.017  60--150 mg/dl89 ± 1169 ± 19\<0.0001  70--180 mg/dl86 ± 1480 ± 19NS Nr of art blood glc measurements/day10 ± 310 ± 4NS Glucose variability parameters  SD (mg/dl)25 (20--36)38 (29--63)0.003  Coefficient of variation (%)25 (20--33)29 (23--44)NS  IQR33 (27--55)45 (35--76)0.031  MAGE (mg/dl)50 (34--72)60 (43--100)0.085  MODD (mg/dl)29 (22--45)42 (32--76)0.005  M-1002 (1--4)6 (4--14)0.001  CONGA1 (mg/dl)15 (12--19)21 (15--35)0.008  CONGA2 (mg/dl)22 (17--28)32 (20--48)0.010  CONGA4 (mg/dl)29 (18--43)42 (27--69)0.011  LBGI2.7 (0.9--3.8)0.7 (0.2--1.9)0.001  HBGI0.3 (0.2--1.1)2.0 (1.4--4.5)\<0.0001  Glucose variability21 (17--28)36 (29--53)\<0.0001Data are presented as numbers, as mean ± SD or median (25--75th percentile)*LOS in ICU* length of stay in ICU, *IQR* interquartile range, *MAGE* mean amplitude of glycemic excursions, *MODD* mean of daily differences, *LBGI* low blood glucose index, *HBGI* high BGI

Characteristics of diabetic versus non-diabetic subjects {#Sec10}
--------------------------------------------------------

No differences in patient demographics except for BMI (*p* = 0.02), in reason for admission, severity of illness, and clinical interventions used, were present between diabetic (*n* = 21) and non-diabetic critically ill patients (Table [3](#Tab3){ref-type="table"}). There were more diabetic patients in the Leuven protocol (*p* = 0.009). Diabetic subjects required more insulin, had a worse median glycemia (131\[110--166\] vs. 116\[107--128\] mg/dl, *p* = 0.034), spent less time in target glycemia (25 ± 12 vs. 36 ± 15%, *p* = 0.006), more time in hypoglycemia (4\[1--10\] vs. 0\[0--1\]%, *p* = 0.001) than non-diabetic subjects. All other glucometrics, including glycemic variability parameters, were worse as well in diabetic patients (see Table [3](#Tab3){ref-type="table"}).Table 3Baseline characteristics, interventions used and glucometrics of non-diabetic versus diabetic patientsNon-DMDMStatisticsNumber of patients3621Patient demographics Men/women19/1711/10NS Age (years)65 ± 1162 ± 12NS BMI (kg/m^2^)26 ± 429 ± 70.02Severity of illness APACHE-II score29 ± 626 ± 7NS SOFA score11 ± 49 ± 3NS (0.064)Clinical interventions Mechanical ventilation2717NS Vasopressor therapy2312NS Hemodialysis122NS (0.06) No/total parenteral/enteral feeding7/13/1610/4/7NS (0.075) Glucocorticoids207NS Antibiotics3016NSProtocol (Leuven/Yale)9/2713/80.009Insulin dose Day 1 (units)48 (26--82)127 (51--175)0.001 Day 2 (units)46 (25--85)113 (67--168)0.009Glucose parameters HbA1c (%)5.9 (5.6--6.3)6.9 (6.1--7.3)\<0.0001 HbA1c (mmol/mol)41 (38--45)52 (43--56)\<0.0001 Median glycemia (mg/dl)116 (107--128)131 (110--166)0.034 % of time at glycemia  \<60 mg/dl0 (0--1)4 (1--10)0.001  80--110 mg/dl36 ± 1525 ± 120.006  \>150 mg/dl32 ± 1524 ± 110.001  \>200 mg/dl3 ± 1515 ± 200.001  60--150 mg/dl83 ± 1263 ± 23\<0.0001  70--180 mg/dl90 ± 1169 ± 19\<0.0001 Nr of art blood glc measurements/day10 ± 410 ± 3NS Glucose variability parameters  SD (mg/dl)28 (21--35)53 (40--75)\<0.0001  Coefficient of variation (%)23 (19--30)38 (29--51)\<0.0001  IQR38 (28--45)66 (41--108)\<0.0001  MAGE (mg/dl)49 (35--66)87 (56--127)0.002  MODD (mg/dl)35 (26--42)59 (35--116)\<0.0001  M-1004 (2--5)12 (6--29)\<0.0001  CONGA1 (mg/dl)15 (13--20)30 (19--41)\<0.0001  CONGA2 (mg/dl)22 (17--30)44 (26--59)\<0.0001  CONGA4 (mg/dl)30 (21--43)60 (37--86)\<0.0001  LBGI0.7 (0.3--1.8)2.3 (0.9--3.7)0.013  HBGI1.2 (0.4--1.8)3.0 (1.4--10.3)0.002  Glucose variability28 (20--34)44 (34--79)\<0.0001Data are presented as numbers, as mean ± SD or median (25--75th percentile)*LOS in ICU* length of stay in ICU, *IQR* interquartile range, *MAGE* mean amplitude of glycemic excursions, *MODD* mean of daily differences, *LBGI* low blood glucose index, *HBGI* high BGI

In the non-diabetic group, patients in the Yale protocol spent more time in target glycemia (40 ± 15 vs. 25 ± 10%, *p* = 0.009), less time in hypoglycemia (0\[0--0\] vs. 1\[0--6\]%, *p* = 0.013), and glycemic variability tended to be smaller (SD *p* = 0.076, CV *p* = 0.057, MODD *p* = 0.021) than those treated by the Leuven protocol. Median glycemia was similar (117\[108--127\] vs. 115\[101--140\]) in both groups (Additional file [1](#MOESM1){ref-type="media"}: Table S1). In the diabetic subjects, insulin needs were lower (*p* = 0.044) and patients spent less time at a glycemia \>150 mg/dl (26 ± 21 vs. 35 ± 25%, *p* = 0.003) in the Yale compared to the Leuven group. However, median glycemia (120\[108--140\] vs. 136\[111--169\] mg/dl), time spent in hypoglycemia or at target range, and parameters of glycemic variability were similar between groups (Additional file [1](#MOESM1){ref-type="media"}: Table S1).

Discussion {#Sec11}
==========

Achieving strict glycemic control without risk of hypoglycemia in the ICU is difficult. It requires a comprehensive and safe insulin infusion protocol (IIP) that is both detailed enough and practical enough to be easily implemented by ICU nurses \[[@CR2], [@CR28]\]. Multiple IIPs have been developed, but to the best of our knowledge this is the first study comparing the clinical efficacy (% time in target glycemia) and safety (hypoglycemia, glycemic variability) of two IIPs in MICU patients by means of CGM. Overall, compared to existing data (see Table [4](#Tab4){ref-type="table"}, \[[@CR3]--[@CR15], [@CR29]--[@CR38]\], both our IIPs were able to obtain reasonably strict glucose control without excessive risk of hypoglycemia. The percentage of time in normoglycemia was higher (37 vs. 26%), and percentage of time in hypoglycemia lower (0 vs. 5%) and glycemic variability was less pronounced in patients treated with the Yale IIP. Diabetes status can, however, be a confounding factor \[[@CR34]\]. We observed an imbalance in the number of diabetic subjects with more diabetic patients in the Leuven group. Diabetic as compared to non-diabetic subjects required more insulin, had worse glycemic control, and larger glycemic variability, thereby possibly blunting the effect of the IIP. However, logistic regression could not identify type of IIP, diabetes status, or severity of illness as independent parameters associated with strict glucose control. When comparing Yale versus Leuven protocol in non-diabetic subjects, patients in the Yale protocol had better glucometrics. This was evident, despite the low number of patients. In the diabetic subgroup, however, the advantages of the Yale protocol were less pronounced.Table 4Summary of several insulin infusion protocols in different ICU settingsAuthorsICU typeStudy*n*% Diabetic patientsProtocolTarget glycemia (mg/dl)Method of glucose measurementsGoldberg et al. (2004)MICUObservational5256Yale100--139Hospital glucose meter: near hourly measurementsVan den Berghe et al. (2006)MICURCT120017Paper: Leuven80--110ABG: q1-4 hKulnik et al. (2008)MICUObservational1020eMPC (computer)80--110Variable sampling rate: q20 min-4 hShetty et al. (2012)MICUObservational9066Yale120--160POC meter: hourly measurementsHolzinger et al. (2010)MICURCT12419Leuven80--110CGMDe Block et al. (2015)MICURCT3523Yale80--110CGMFinney et al. (2003)MixedObservational52316Paper90--145ABGJuneja et al. (2007)MixedObservational2398NRClarian Gluco Stabilizer80--110POC: q1-2 hChase et al. (2008)MixedObservational37117SPRINT80--110Sampling rate: q1-2 hMorris et al. (2008)MixedBefore--after755NReProtocol-insulin versus paper80--110POC: q1-4 hPreiser et al. GLUCONTROL (2009)MixedRCT107821Paper: glucontrol80--110POC: q1-4 hNICE SUGAR (2009)MixedRCT610420Paper: Leuven81--108ABGMarvin et al. (2013)MixedRetrospective1657NRComputerized Yale100--140POC: variable time intervalVan Herpe et al. (2013)MixedRCT30021LOGIC-insulin computerized80--110ABG: variable time interval: q1-4 hKrinsley et al. (2015)MixedRetrospective329723Paper: Stamford70--140POC: q3 hVogelzang et al. (2005)SICUObservational17915GRIP72--135POC blood gas analyzer: variablePlank et al. (2006)SICU: cardiothoracic surgeryRCT6023eMPC versus paper80--110POC: variable sampling rate: q1 h-4 hHovorka et al. (2007)SICU: cardiac surgeryRCT6045eMPC80--110Variable sampling rate: q1 h-4 hSaager et al. (2008)SICU: cardiothoracic ICURCT40100EndoTool (computer) versus paper90--150POC: hourlyDortch et al. (2008)SICU: trauma ICURCT552Computer versus paper80--110POC q1-4 hBlaha et al. (2009)SICU: cardiac surgeryRCT12014eMPC versus paper (Matias versus Bath)80--110ABG: protocol dependent: q1-4 hBarletta et al. (2011)SICUBefore--after19228Computer versus paper80--110POC: variable sampling rate: q30 min-2 h versus q2 hDumont et al. (2012)SICU: cardiovascular ICURCT30043Computer (EndoTool) versus paper (modified Portland)80--150NAAuthorsDuration of glucose monitoringGlucometric to measure target% of time at target glycemia: intervention versus control groupMean glycemia (mg/dl): intervention versus control groupHypoglycemia: intervention versus control groupGlycemic variabilityReferencesGoldberg et al. (2004)61 hPercent of hourly BG values in target range52%124 ± 15% of data at glc \<60 mg/dl: 0.3%NA\[[@CR8]\]Van den Berghe et al. (2006)NRMean morning BGNA111 ± 29 versus 153 ± 31% of patients: glc \<40 mg/dl: 18.7 versus 3.1%NA\[[@CR13]\]Kulnik et al. (2008)72 hPercent of BG values in target47 ± 13%109 ± 13% data at glc \<40 mg/dl: 0%NA\[[@CR15]\]Shetty et al. (2012)59 hPercent of BG values in target range42%156 ± 23% of data \<70 mg/dl: 0.3%NA\[[@CR37]\]Holzinger et al. (2010)72 hCGM data: percent of data in target range59 ± 20 versus 55 ± 18106 ± 18 versus 111 ± 10Rate: 1.9% versus 11.5%NA\[[@CR9]\]De Block et al. (2015)96 hCGM data: percent of data in target range37 ± 12 versus 34 ± 10119 ± 17 versus 122 ± 11% of time at glc \<60 mg/dl: 0.6 ± 1.6 versus 2.4 ± 4.3%No differences between groups in SD, MAGE, MODD, CV\[[@CR6]\]Finney et al. (2003)22--89 hTime spent in glucose band 80--110 mg/dl4 (0--20)%NR0 ± 1%NA\[[@CR31]\]Juneja et al. (2007)NRPercent of data in target range52 versus 32%107 ± 39% data at glc \<50 mg/dl: 0.4 versus 0.5%NA\[[@CR10]\]Chase et al. (2008)53 hPercent of BG values in target54%108 ± 27% of data at glc \<72 mg/dl: 3.8%SD: 27 mg/dl\[[@CR4]\]Morris et al. (2008)4--22 daysPercent of BG values in target42 versus 28%116 versus 134% data at glc \<40 mg/dl: 11.1 versus 5.1%NA\[[@CR11]\]Preiser et al. GLUCONTROL (2009)48--216 h (=2--9 days)Proportion of time of BG values in range43%117 (IQR: 108--130) mg/dlProportion of time at glc \<40 mg/dl: 5.9 ± 27%SD: 36 mg/dl\[[@CR12]\]NICE SUGAR (2009)4.2 days (1.9--9.0 days)Time-weighted mean BGNR115 ± 18 versus 144 ± 23% of patients: glc \<40 mg/dl: 6.8 versus 0.5%NA\[[@CR7]\]Marvin et al. (2013)NRPercent of hourly BG values in target range92%124% of data 40--70 mg/dl: 1.1% and in 17.6% of patientsNA\[[@CR34]\]Van Herpe et al. (2013)26--113 hPercent of BG values in target range69 ± 17 versus 60 ± 19106 ± 9 versus 107 ± 11% data at glc \<60 mg/dl: 0.6 versus 1.2%Max change in glc/24 h: 31 versus 37 mg/dl\[[@CR14]\]Krinsley et al. (2015)36--120 hPercent of time of BG values in target rangeNon-DM versus DM: 81 (61--94) versus 55 (35--71)%Non-DM versus DM: 121 (112--133) versus 140 (128--155) mg/dl% of patients: glc \<70 mg/dl: non-DM versus DM: 18 versus 31%CV: non-DM versus DM: 18 versus 27%\[[@CR33]\]Vogelzang et al. (2005)1.6 (0.8--4.7) daysPercent of time of BG values in target78 (66--88)%121 (108--135)% of patients: glc \<40: 0.6%; glc \<63: 11.2%NA\[[@CR38]\]Plank et al. (2006)48 hPercent of time in target range52 (17--92) versus 19 (0--71)%117 (102--144) versus 131 (97--237)Number of hypo episodes (\<54 mg/dl) over 48 h: 0 versus 2NA\[[@CR35]\]Hovorka et al. (2007)24 hPercent of time in target range60 ± 23 versus 28 ± 16112 ± 20 versus 130 ± 20% of data at glc \<52 mg/dl: 0% versus 0%NA\[[@CR32]\]Saager et al. (2008)9 hPercent of BG values in target84 versus 60%126 ± 18 versus 147 ± 27Episodes of hypo (\<60 mg/dl) during ICU: 4 versus 1NA\[[@CR36]\]Dortch et al. (2008)NRPercent of BG values in target42 versus 34%116 ± 37 versus 120 ± 37% data at glc \<40 mg/dl: 0.2 versus 0.5%NA\[[@CR30]\]Blaha et al. (2009)45--48 hTime in target range46 ± 3 versus 38 ± 3 versus 40 ± 3%106 ± 4 versus 121 ± 4 versus 117 ± 4Time in hypo (\<52 mg/dl): 0 ± 0 versus 0.4 ± 0.2 versus 0.4 ± 0.3%NA\[[@CR18]\]Barletta et al. (2011)67 versus 98 hPercent of BG values in target49 ± 14 versus 40 ± 12113 ± 11 versus 116 ± 11% data at glc \<40 mg/dl: 2.1 versus 4.1%SD: 25 ± 9 versus 31 ± 11 mg/dl\[[@CR29]\]Dumont et al. (2012)NAPercent of BG values in target range70 ± 15 versus 62 ± 18138 ± 16 versus 141 ± 20Number of hypo events \<60 mg/dl: 7 (5%) versus 18 (11%)SD:36 ± 18 versus 42 ± 21\[[@CR19]\]*MICU* medical intensive care unit, *SICU* surgical ICU, *RCT* randomized controlled trial, *NR* not reported, *NA* not assessed, *ABG* arterial blood glucose, *POC* point of care, *SD* standard deviation

Up till now no single IIP has been established as the most effective for obtaining tight glycemic control \[[@CR28], [@CR39], [@CR40]\]. The IIP should be tailored to the subset of patients being treated and to local resources, because an excellent validated IIP is no guarantee for optimal glucose control unless it is carefully implemented. Most IIPs show significant similarities, but differences relate to target glucose levels (80--110 mg/dl versus ranges varying between 90 and 180 mg/dl), initial glycemic threshold (\>150--200 mg/dl), infusion rates, use of boluses, and frequency of monitoring. Changes in insulin infusion rate may relate to actual glycemia, direction and/or velocity of change in glycemia, degree of insulin resistance, and insulin dose. The population treated (surgical vs. medical ICU, diabetes status) may also affect the performance of the IIP \[[@CR2], [@CR28], [@CR39], [@CR40]\]. The competence of the nurses and clarity of instructions also influence outcome. Computerized decision-supported algorithms might provide superior glucose control compared to paper-based IIPs because of reduced errors by enabling the use of complex mathematical calculations and better protocol consistency. In MICUs and mixed ICUs where a glycemia between 80 and 110 mg/dl was targeted, 22--60% of all blood glucose values were reported to be in target for paper-based IIPs \[[@CR3]--[@CR14]\], compared to a higher percentage (42--69%) for computerized IIPs \[[@CR4], [@CR10], [@CR11], [@CR14], [@CR15]\] (Additional file [1](#MOESM1){ref-type="media"}: Digital Content--Table S1). In contrast, in a before--after study in 192 surgical ICU patients, Barletta et al. \[[@CR29]\] could not observe significant glucometric differences between the computer-assisted versus paper-based IIP. It is probably not the paper or computer that makes the largest difference; but the IIP algorithm itself and the competence of the staff.

A head-to-head comparison of different IIPs on glycemic control has only been performed in RCTs in cardiac surgery. Blaha et al. \[[@CR18]\] compared two paper protocols with a computerized IIP in 120 patients, showing that the computerized IIP provided better average glucose control, but with a longer time in hypoglycemia risk range than the paper protocols. Dumont and Bourguignon \[[@CR19]\] compared the effect of a computerized (EndoTool) versus a paper IIP (modified Portland protocol) in 300 ICU patients, showing better glucose control and nurses' satisfaction with the EndoTool IIP. In both studies, however, it was not only the protocol that differed but also the way it was implemented (paper vs. computerized), making it difficult to assess the true value of the protocol itself.

Measurement frequency is an inherent part of an IIP and will affect glucometrics. Recently, the effect of the IIP (Yale vs. University of Washington), frequency of glucose measurements (hourly vs. every 5 min), and measurement imprecision on glycemic control efficacy was studied using a simulation model \[[@CR16]\]. In both IIPs, the rates of hypo- and hyperglycemia and of glycemic variability increased with increasing measurement imprecision. Others investigated the performance of the IIP versus methodology of glucose measurements (blood glucose meter vs. CGM) at different levels of measurement accuracy \[[@CR17]\]. The protocol itself proved to have a greater effect on glycemic control efficacy than the glucose measurement method, with the Yale protocol showing the best performance. However, hypoglycemia risk was lower in CGM-informed IIPs \[[@CR17]\]. Thus, efficacy of the IIP together with performance and accuracy of the CGM device used both contribute to the success of tight glucose control. In the future, validated computerized IIPs can be guided by real-time CGM in a semi-closed loop, thereby improving efficacy, safety and reducing nursing workload.

Comparison of glucometrics between studies using different IIPs is difficult due to differences in population, target glycemia, and frequency of glucose monitoring. In addition, many different glucometrics are reported in different studies, including metrics of central tendency (mean or median glycemia, time-averaged glucose, admission glycemia, proportion of glucose values in target), metrics of extremes (percentages or episodes of hypo- or hyperglycemia), and metrics of dispersion (SD, coefficient of variation, MAGE). The robustness of glucometrics depends largely on the number of measurements per time unit used for its calculation. Accurate assessment of time in target glycemia, or in hypo- or hyperglycemia, and of glucose variability can only be done by using validated CGM methodology.

Our study has some limitations and strengths. This is a pooled data analysis of two prospective RCTs conducted at the medical ICUs, using relatively old data. Indeed, patients were recruited between 04/2004 and 03/2005 for the first study and between 07/2007 and 09/2009 for the second study. However, pooling the CGM data is justifiable in our opinion because the same CGM sensor was used in both studies and the study population and standards of care in both services were comparable. However, our results might not be applicable to a mixed or surgical ICU setting. Despite more than 63,000 CGM glucose measurements being available for analysis, due to the small number of patients and heterogeneity of groups, statistical superiority of the Yale protocol could not be proven.

A major strength, in our opinion, when comparing IIPs, is the use of CGM data which provides a complete picture of glucometrics. We did not make use of study nurses particularly focused on glucose control, but implemented our study in a routine clinical setting, allowing a more clinically relevant picture.

In summary, the use of a safe and efficient IIP is a prerequisite to correctly implement strict glycemic targets. Both IIPs have proven to balance efficacy with safety (avoid hypoglycemia and glycemic variability) and attainability (nursing workload). Overall, the modified Yale protocol provided better glucose control with more time spent in normoglycemia, less time spent in hypoglycemia, and less glycemic variability as compared to the Leuven protocol.

Additional file {#Sec12}
===============

**Additional file 1: Table S1.** Baseline characteristics and glucometrics of patients treated by the Leuven versus Yale protocol, analysed according to diabetes status.

BMI

:   body mass index

CGM

:   continuous glucose monitoring

CONGA

:   continuous overlapping net glycemic

HBGI

:   high blood glucose index

ICU

:   intensive care unit

IIP

:   insulin infusion protocol

IV

:   intravenous

LBGI

:   low blood glucose index

MAGE

:   mean amplitude of glucose excursions

MICU

:   medical intensive care unit

MODD

:   mean of daily differences

RCT

:   randomized controlled trial(s)

SD

:   standard deviation

UZA

:   Universitair Ziekenhuis Antwerpen (Antwerp University Hospital)
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